What is the appropriate dosing of apixaban (Eliquis) for an 80-year-old patient with an estimated glomerular filtration rate of 30 mL/min?

Apixaban Dosing in an 80-Year-Old with GFR 30 mL/min

Start apixaban 5 mg twice daily unless the patient also has either a body weight ≤60 kg OR serum creatinine ≥1.5 mg/dL, in which case use 2.5 mg twice daily. Age ≥80 years alone is not sufficient to warrant dose reduction—you need at least two of the three dose-reduction criteria.

Dose Reduction Criteria

The FDA-approved dosing algorithm for apixaban in atrial fibrillation is straightforward 1:

• Standard dose: 5 mg twice daily
• Reduced dose (2.5 mg twice daily): Required when at least 2 of 3 criteria are present:
  1. Age ≥80 years
  2. Body weight ≤60 kg
  3. Serum creatinine ≥1.5 mg/dL

Your Patient's Situation

Your 80-year-old patient meets one criterion (age ≥80). With a GFR of 30 mL/min, you need to determine:

1. Body weight: Is it ≤60 kg?
2. Serum creatinine: Is it ≥1.5 mg/dL?

If either is present → 2.5 mg twice daily
If neither is present → 5 mg twice daily

Note that GFR 30 mL/min typically corresponds to a serum creatinine ≥1.5 mg/dL in most patients, making the 2.5 mg dose more likely appropriate, but you must verify the actual creatinine value.

Evidence Supporting This Approach

The ARISTOTLE trial established this dosing strategy 2. In that study, patients with moderate renal impairment (CrCl 30-50 mL/min) predominantly received 5 mg twice daily (1,063 patients) rather than 2.5 mg (294 patients), and apixaban demonstrated superior efficacy and safety compared to warfarin across all renal function categories 2. The reduction in major bleeding was actually more pronounced in patients with impaired renal function 2.

The Canadian guidelines explicitly state that for CrCl 30-49 mL/min, the standard dose is 5 mg twice daily, with consideration of 2.5 mg twice daily only when the full dose-reduction criteria are met 2.

Critical Pitfalls to Avoid

Do not automatically reduce the dose based on renal function alone. The most common error is assuming that GFR 30 mL/min mandates dose reduction—it does not 2. Apixaban has only 27% renal excretion 1, making it less dependent on renal clearance than dabigatran (80% renal) or rivaroxaban (66% renal).

Verify you're using the correct creatinine clearance calculation. The FDA guidance and clinical trials used Cockcroft-Gault equation, not eGFR 3. While recent guidance is moving toward eGFR, the dose-reduction criteria specifically reference serum creatinine ≥1.5 mg/dL as the threshold, not a calculated clearance.

Safety Considerations at GFR 30 mL/min

Recent real-world data shows that in patients with severe CKD (GFR 15-30 mL/min), the 5 mg dose was associated with higher bleeding risk compared to 2.5 mg, without additional benefit in preventing stroke 4. However, your patient is at the upper end of this range (GFR 30), where evidence is more limited.

The ARISTOTLE trial included very few patients with CrCl 15-29 mL/min (only 1.5% of the trial population) 2, so data in severe renal impairment remains sparse. For CrCl 15-29 mL/min, guidelines note "very limited RCT data" 2.

Monitoring Recommendations

Once initiated, monitor for:

• Bleeding complications (particularly if using 5 mg dose with borderline renal function)
• Renal function decline (reassess dose if GFR drops below 25 mL/min)
• Drug interactions with P-glycoprotein and CYP3A4 inhibitors, which require dose reduction 1

The 2.5 mg dose should be avoided entirely if the patient is taking combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) 1.